BETHESDA, Md., Oct. 4, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it will be presenting at the second annual Cancer Immunotherapy: A Long-Awaited Reality Conference on Thursday, October 6, at the New York Academy of Medicine in New York City. The single-day conference unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy that is now coming of age.
Dr. Anthony Maida, COO, and Mr. Leslie J. Goldman, Sr. Vice President for Business Development, of NORTHWEST BIO will be making the presentation. They will be presenting the science of DCVax®, the promising clinical data generated to date, and the progress of the Company's pipeline of multiple individualized cancer vaccine products. They will indicate how NORTHWEST BIO's developing immunotherapy products hold the promise of treating cancers more effectively than the current standard of care, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the US and Europe.
Ms. Linda Powers, CEO of NORTHWEST BIO said, "This topic and conference are particularly timely in view of yesterday's Nobel Prize in Medicine for certain key discoveries about the immune system – especially about the critical role of dendritic cells. At NORTHWEST BIO, we have developed medical treatments for cancer using these same dendritic cells, whose discovery by Dr. Ralph Steinman now has earned the Nobel Prize. Our medical treatments are one of the first personalized medicines to apply this potential: they make use of the patient's own dendritic cells, which are activated and "educated" to mobilize the immune system to attack that patient's particular cancer."
"We have been developing these dendritic cell treatments for over a decade and have now reached late stage clinical trials," Ms. Powers continued. "In the trials so far, patients who received the DCVax® dendritic cell treatments lived for years longer than patients receiving standard of care (not just weeks or months longer), and without toxicity. Building upon the original discovery of dendritic cells by Dr. Steinman, we are working to make dendritic cell treatments widely available for patients, and believe that such treatments have the potential to become a new standard of care for most cancers."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV